NCAM1 and COVID-19: A specific set of markers were evaluated in ILC (See Table S3); in fact, in COVID-19 patients CD56 was decreased in ILC1, while in ILC2 and ILCp was increased CD69 and only ILC2 decreased CD62L [55] (See Figure 1D).